Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[bhp1rtp]

UPREGULATE THE ANTI-INFLAMMATORY CYTOKINES AND INHIBIT THE PROINFLAMMATORY CYTOKINES

Nuke John I have also been looking into GSK3

Like you I also found lots of information on GSK3. I found a 2012 article which contained the above words (upregulate the anti-inflammatory cytokines and to inhibit the proinflammatory cytokines). My first thought was this is exactly what all the science on Anatabine boils down to. The whole quote is

“Remarkably, PI3K and mTOR seem to upregulate the anti-inflammatory cytokines and to inhibit the proinflammatory cytokines”

The title of the report is

Roles of PI3K/AKT/GSK3/mTOR Pathway in Cell Signaling of Mental Illnesses

The report is published in a 2012 issue of Depression Research and Treatment

The report ends with this paragraph

“The possible involvement of the PI3K/AKT/GSK3/mTOR in signaling evoked by the neuromonoamine has remained unexplored. Between angiogenesis and neurogenesis, there might be common pathways including the PI3K/AKT/GSK3/mTOR pathway. Whereas many questions remain to be answered about the role of the PI3K/AKT/GSK3/mTOR signaling in mental disorders, it is possible that the inhibition of the signaling in specific neuronal populations could be associated with distinct behavioral outcomes [4, 6, 59]. More understanding of the precise intracellular mechanisms downstream of PI3K/AKT/GSK3/mTOR changes in mental illnesses could provide novel insights into the development of new therapeutic approaches having greater efficacy against major depression.”

Roskamp Institute published Anatabine Attenuates Tau Phosphorylation and Oligomerization in P301S Tau Transgenic Mice on May 21, 2014 in Brain Disorders & Therapy.

In this report it appears that Roskamp has increased both the downstream and the upstream understanding of the precise intracellular mechanisms of PI3K/AKT/GSK3

http://omicsonline.org/search-related-journal-articles.php

The report states “It is likely that the inhibition of STAT3 and NFkB observed is consequent to the inactivation of GSK3ß by anatabine, as both STAT3 and NFkB activation are highly dependent on GSK3ß activity [60,61]. We have summarized on Figure 12 a possible mechanism of action for anatabine that highlights its potential therapeutical application in AD.

In looking at figure 12 it appears to me that Roskamp is placing Anatabine and nAChR upstream of P13K and they are placing Tau-P, STAT3, and NFkb downstream of GSK3b. Downstream of STAT3, and NFkB Roskamp has Neuroinflammation and BACE-1 and downstream of BACE-1 is B-Amyloid.

http://omicsgroup.org/journals/BDTimages/2168-975X-3-126-g012.html